Monitors will verify during a review of a CRS's regulatory binder that every investigator listed on all Form FDA 1572s has accurately completed and signed either the DAIDS approved network financial disclosure form/statement or the drug company-specific financial disclosure form/statement for that clinical trial. The effective date for this process is July 1, 2014.